^
Association details:
| Biomarker: | PD-L1 negative |
|---|---|
| Cancer: | Cervical Cancer |
| Drug: | balstilimab (AGEN2034) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
Published date:
08/24/2021
Excerpt:
In patients with PD-L1-positive tumors the ORR was 20%, however patients with PD-L1-negative tumors also responded to balstilimab (ORR, 7.9%). Balstilimab demonstrated meaningful and durable clinical activity, with manageable safety, in patients with previously-treated, recurrent/metastatic cervical cancer.
DOI:
10.1016/j.ygyno.2021.08.018
